BioNetwork East 2008

GET INVOLVED

EVENT DETAILS

Home
Who Should Attend?
Conference Agenda
Past Attendees
Partnering Primers
Therapeutic Roundtables
Partnering Rooms
Conference Pricing

DELEGATE INFORMATION

FAQs
Venue Information
Speaker Information

WBR

WBR Home
Related Events
Contact Us

Main Conference Agenda At-a-Glance

Day One - Monday, March 17, 2008


7:10	Networking Breakfast And Conference Registration

8:10	Opening Remarks And Event Introduction Rebecca Whitehead, Executive Director, BioNetwork East

8:15	Chairperson’s Opening Remarks

8:30	Where Are We And Where Are We Going? Bethany Mancilla, Vice President, Business Development, Pharmathene Peter Condon, Associate Director, Business Development, Genentech Dan Passeri, CEO, Curis

9:00	Partnering Primer I: Universities And Emerging Biotechs Lyndal Hesterberg, Ph.D., President and CEO, BaroFold Ira Weiss, Vice President of Finance and Operations, BioDtech, Inc. Dan Passeri, CEO, Curis

9:30	Partnering Primer II: Small Biotech Companies Kia Motesharei, Vice President, Business Development, Genfit Corp. David Wurtman, Vice President of Corporate Development, NexBio Ralph Snodgrass, Chief Executive Officer, VistaGen.

10:00	Morning Networking And Refreshment Break

10:30	Partnering Primer III: Medium and Large Biotech Companies Peter Condon, Associate Director, Business Development, Genentech Jim Gilligan, Vice President for Product Development, Unigene Laboratories

10:50	Partnering Primer IV: International Companies Located In Japan, India, China And Canada Nick Manusos, Vice President Business Development, Takeda Pharmaceuticals - Japan

11:10	Partnering Primer V: Specific Therapeutic Areas Of Interest Oncology, Cardiology, Infectious Disease, Metabolic Disorders, And More! John Peck, Co-Founder, Mesa Therapeutics, Oncology Donald Olsen, VP, Licensing & Business Development, Ortho Biotech David Kalergis, CEO, Diffusion Pharmaceuticals Bethany Mancilla, VP Business Development, Pharmathene, Alzheimer’s James Vlazny, Licensing Consultant, Cook Biotech, Oncology Vaccine

12:00	Lunch And Networking Break

1:00	Partnering Primer VI: Specialty Pharmaceuticals Tom Reilly, Ph.D., MBA, Vice President, BTG International Inc. Jim Hattersley, Vice President Corporate Business Development, Antares Pharma Tom Heck, Vice President Business Development,Victory Pharma

1:30	Pharmaceutical Partnering Opportunities Scott Kennedy, PhD, Executive Director, Worldwide Exploratory Science and Technology,, External Research Network, East Region and Canada,Pfizer Mark Miller, Senior Director Corporate Business Development, Lilly Mike Leonetti, Head of Healthcare Partnerships, Boehringer Ingelheim Pharmaceuticals Inc. Jules Musing, Vice President, Licensing & Development, Johnson & Johnson John Poulos, Group Vice President, Global Pharmaceutical, Licensing and New Business Development, Abbott Michael Schultz, Vice President, New Business Ventures, Global Business Development, & Licensing, Bayer Schering Pharma AG

2:30	Afternoon Networking And Refreshment Break

3:00	Champagne Roundtable Discussions Focusing On Specific Therapeutic Areas Of Interest: The Quickest Path For Uncovering Finite Partnering Opportunities Sponsored By MattsonJack, Arthur D. Little, NovaQuest, Upsher-Smith

5:30	Welcome Reception Sponsored By Abbott

Day Two - Tuesday, March 18, 2008


7:15	Networking Breakfast And Conference Registration

8:15	Chairperson’s Opening Remarks Michael Herman, Partner, Gowling Lafleur Henderson LLP

8:30	Scouting Early Stage Relationships To Achieve Later-Day-Deals Paul Medeiros, Vice President Global Licensing, Schering-Plough Michael Schultz, Vice President, New Business Ventures, Global Business Development, & Licensing, Bayer Schering Pharma AG Jennifer Griffiths, Head Search and Evaluation, AB, Novartis Pharmaceuticals Corporation Donald Olsen, VP, Licensing & Business Development, Ortho Biotech

9:05	Bureaucracy Unbundled: Dissecting Large Pharma To Help Quickly Identify Partners And Position Yourself As A Partner Of Choice John Poulos, Group Vice President, Global Pharmaceutical, Licensing and New Business Development, Abbott Mark Miller, Senior Director, Corporate Business Development, Lilly Jules Musing, Vice President Licensing & Development, Johnson & Johnson Scott Kennedy, PhD, Executive Director, Worldwide Exploratory Science and Technology, External Research Network, East Region and Canada, Pfizer

9:40	Building A Franchise Through Partnerships: A Detailed Account Of Merck’s Dos And Don’ts Linda Egger, PhD, Director, Scientific Liaison, Oncology, External Scientific Affairs, Merck & Co., Inc.

10:15	Morning Networking And Refreshment Break

10:45	Working With Universities: Discover The Relationship On The Leading Edge In Scientific Innovation Lyndal Hesterberg, Ph.D., President and CEO, BaroFold Ira Weiss, Vice President of Finance and Operations, BioDtech, Inc. David Kalergis, CEO, Diffusion Pharmaceuticals

11:20	Securing the Future Of Your Company By First Maximizing Current Assets, Including The Ones That Aren’t So Obvious David Wurtman, Vice President of Corporate Development, NexBio

11:55	Building (or Stumbling) Blocks of Global Deal Assessment Joseph S. Dillon, Senior Vice President, Corporate Development Services, MattsonJack

12:30	Lunch And Networking Break

1:30	The New Look Of Biotech/Pharma Partnerships: Forming Prosperous Deals To Return Discontinued Compounds Back To Promising Development Paths Deborah Barbara, VP Business Development and Licensing, Ore Pharmaceuticals Eric De La Fortelle, Global Head, External Research and Technology, Roche

2:05	Extending Product Lifecycle And Reinvigorating Mature Brands Through Innovative Drug Delivery Technologies Pavan Handa, Vice President of Business Development, Noven Pharmaceuticals

2:40	Working With The Changing Role Of Venture Capitalists In Today’s Progressing Financial Market Dennis Purcell, Senior Managing Director, Aisling Capital

3:15	Afternoon Networking And Refreshment Break

3:45	Critical Issues: Roundtables Focused On Your Most Pressing Business Challenges

5:00	Guest Speaker David Ewing Duncan

6:00	Cocktail Reception Hosted By King Pharmaceuticals

Day Three - Wednesday, March 19, 2008


7:15	Continental Breakfast And Conference Registration


8:15	Chairperson’s Opening Remarks Jeffrey Totten, Vice President, Dean & Company

8:30	Repositioning And Reformulation In Building A Specialty Pharma Pipeline Tom Reilly, Ph.D., MBA, Vice President, BTG International Inc.

9:05	Deal Killers: Successfully Navigating Through The Due Diligence Minefield Len Smith, Senior Intellectual Property Counsel, Novo Nordisk, Inc. Susan Thorpe, Senior Licensing Director, Business Development, Novo Nordisk, Inc. David King, PhD, Senior Regulatory Intelligence Officer, Novo Nordisk, Inc.

9:40	The Growing Business in Canada - Stretching US and International Biotech Company Funds Through Canadian R&D partners Sharon Bennett, Partner, Gowling Lafleur Henderson LLP Robert Ford, Partner, Gowling Lafleur Henderson LLP

10:15	Morning Networking And Refreshment Break

10:45	Current Experiences And Approaches To Alliance Management: A Detailed Look Into Different Philosophies Ellen Locker, Executive Director, Alliance Management, Merck and Co. Inc Mike Leonetti, Head of Healthcare Partnerships, Boehringer Ingelheim

11:20	Achieving Global Harmony: Successfully Managing Alliances Overseas Nick Manusos, Vice President, Business Development, Takeda Pharmaceuticals Christopher Seaton, Senior Vice President,Global Transactions, Bayer Healthcare Pharmaceuticals Kia Motesharei, Vice President, Business Development, Genfit Corp. John Brennan, Managing Director and Global Practice Leader, Life Sciences Practice, Arthur D. Little

11:55	Products Dying On The Vine? How Business Development Can Maximize The Profitability And Lifecycle Of A Branded Drug Adriann Sax, Executive Vice President, Business Development and Strategic Planning, King Pharmaceuticals

12:30	Lunch And Networking Break

1:30	A Tale Of Three Deals: A Detailed Look Into The Different Collaboration Approaches Within One Company Troy Windt, Senior Director of Corporate Development, Upsher-Smith

2:05	Specialty Pharma: The Evolution Of Positive Growth Jim Hattersley, Vice President Corporate Business Development, Antares Pharma Tom Heck, Vice President Business Development, Victory Pharma Troy Windt, Senior Director of Corporate Development, Upsher-Smith Pavan Handa, Vice President, Business Development, Noven Pharmaceuticals, Inc. John Peck, Co-Founder, Mesa Therapeutics

2:40	Forever Young: Optimizing The Success Of Managed Alliances Heidi Towers, Director of Project Management, MedImmune Limited Michele Keough, Senior Director Program Management, Genzyme

3:15	Afternoon Networking And Refreshment Break

3:30	Achieving Efficient Pharma IP And Patent Procedures In Accordance With FDA Regulations: Understanding, Not Only The Whats, But The Hows Len Smith, Senior Intellectual Property Counsel, Novo Nordisk, Inc.

4:05	The Role of Metal Coordination Chemistry in the Modulation of Drug Pharmacokinetics Dr. Thomas Piccariello, President & Chief Scientific Officer,Synthonics Inc. Ken Slepicka, CEO, Synthonics Inc.

4:40	Conclusion Of BioNetwork East 2008